ORIC Pharmaceuticals, Inc. (ORIC) Stock Price & Analysis
ORIC Pharmaceuticals, Inc. (ORIC) closed at USD 13.63 on Thursday, October 22, 2026, down 1.59% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 13.85; the Oct 22, 2026 session ranged USD 13.38–14.14 on volume of 1,150,320 shares. Market capitalization is $1.41B, with a 52-week range of USD 7.23–14.68 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ORIC.md
Key facts (ORIC)
- 1 of 80 tracked superinvestors hold ORIC (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 1.94 on a 1–5 scale) (16 analysts), mean target USD 21.64 (range 14–27).
- Total return with dividends: 1Y +9.7% vs S&P 500 +14.9%; 5Y -8.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.38, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ORIC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$78.9M | -$91.8M | -$111M | -$143M | -$143M | -$156M |
| Net income | -$78.7M | -$89.1M | -$101M | -$128M | -$129M | -$140M |
| EPS (diluted) | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 | — |
| Free cash flow | -$60.5M | -$77.2M | -$86.5M | -$114M | -$112M | -$112M |
| Cash + short-term investments | $237M | $206M | $208M | $256M | $281M | — |
| Total debt | $10.5M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ORIC)
P/B 3.7x · FCF yield -7.95% · Earnings yield -9.93%
Superinvestors (SEC 13F-HR, Q2 2026) (ORIC)
1 of 80 tracked investors hold ORIC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.16% | $55.5M | Reduced -12.0% |
Analysts (ORIC)
Consensus Buy (mean 1.94 on a 1–5 scale), 16 analysts; mean target USD 21.64 (low 14, high 27).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | JP Morgan | Target raised | Overweight | $23 → $26 |
| 2026-10-05 | Leerink Partners | Initiated | Outperform | $26 |
| 2026-09-23 | BTIG | Initiated | Buy | $26 |
| 2026-08-10 | HC Wainwright & Co. | Target raised | Buy | $25 → $27 |
Total return (dividends reinvested) (ORIC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +9.7% | -8.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +9.8% | -1.8% |
| Volatility (annualized) | 88.5% | 88.3% |
| Max drawdown | -46.1% (Mar 2026→Apr 2026) | -86.0% (Nov 2021→Oct 2022) |
ORIC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.38 | $-0.37 | +1.9% | $0 | 13 |
| Next quarter (ends Dec 2026) | $-0.40 | $-0.39 | +1.6% | $0 | 13 |
| Current fiscal year (ends Dec 2026) | $-1.49 | $-1.47 | +1.5% | $0 | 13 |
| Next fiscal year (ends Dec 2027) | $-1.67 | $-1.61 | +3.6% | $0 | 13 |
ORIC options: expected move
Options price a move of about ±38.8% (±$5.38) by Nov 20, 2026, which includes earnings on Nov 12, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 174.9% | ±38.8% |
| Dec 18, 2026 | 56 | 165.4% | ±50.9% |
| Jan 15, 2027 | 84 | 175.2% | ±65.0% |
| Feb 19, 2027 | 119 | 163.9% | ±71.5% |
| May 21, 2027 | 210 | 145.3% | ±82.3% |
30-day implied volatility 172.3% vs 56.8% realized over the last 30 trading days. Put/call ratio (volume) 0.34. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 13.63 |
|---|---|
| Change | ▼ 1.59% (down) |
| Previous Close | USD 13.85 |
| Open | USD 13.57 |
| Day Range | USD 13.38 – 14.14 |
| 52-Week Range | USD 7.23 – 14.68 |
| Volume | 1,150,320 shares |
| Market Cap | $1.41B |
| Exchange | NMS |
Technical Analysis (ORIC)
Nexqual's technical model rates ORIC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.87 (neutral) |
| vs SMA50 | Above (USD 12.96) |
| MACD | 0.14 (positive) |
Analyst Ratings (ORIC)
Wall Street analysts rate ORIC "Buy" based on 16 analysts, with a mean price target of USD 21.64 (range USD 14–27), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 21.64 |
| High Target | USD 27 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (ORIC)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.38 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.38 vs est -0.36 ▼ miss |
| 2026-03-31 | USD -0.34 vs est -0.32 ▼ miss |
| 2025-12-31 | USD -0.3 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.4 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (ORIC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -39.80% |
| Debt / Equity | 0.02 |
| Current Ratio | 13.19 |
| Total Cash | $264.76M |
| Total Debt | $6.00M |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (ORIC)
Nexqual rates ORIC Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $265M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$111M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -40%, ROA -26.0% |
Ownership (ORIC)
| Insider Ownership | +1.59% |
|---|---|
| Institutional Ownership | +123.41% |
| Shares Outstanding | 103.65M |
| Float | 88.69M |
| Short % of Float | +15.91% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (ORIC)
ORIC Pharmaceuticals, Inc. is led by Jacob M. Chacko, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| President, CEO & Director | Jacob M. Chacko |
|---|---|
| Founder, Independent Chairman & Member of Scientific Advisory Board | Richard A. Heyman |
| Chief Financial Officer | Dominic G. Piscitelli |
| Chief Scientific Officer | Lori Sickels Friedman |
| Executive Vice President of Clinical Development | Edna Chow Maneval |
Major Backers & Investors (ORIC)
Notable institutional backers of ORIC Pharmaceuticals, Inc. include Nextech Invest, Ltd., EcoR1 Capital, LLC, Price (T.Rowe) Associates Inc, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nextech Invest, Ltd. | 6.91% |
| EcoR1 Capital, LLC | 6.49% |
| Price (T.Rowe) Associates Inc | 6.38% |
| Viking Global | 4.95% |
| SR One Capital Management, LP | 4.45% |
| Venrock Adviser, LLC | 4.17% |
| NEA Management Company, LLC | 3.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.58% |
| State Street | 4.72% |
| Vanguard Group | 3.81% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt